AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca Plc (NASDAQ:AZN) said Tuesday it will voluntarily delist its American Depositary Shares and certain guaranteed debt securities from the Nasdaq as it transitions to a direct stock listing on the New York Stock Exchange (NYSE). The company previously announced that its ordinary shares and the affected debt securities will begin trading on the NYSE following market close on January 30, 2026, with trading expected to start on February 2, 2026. The Nasdaq listings are expected to cease on January 30. The move is part of AstraZeneca's shareholder-approved plan to harmonize its listing structure into a single global framework. After the change, investors will be able to trade AstraZeneca ordinary shares across the London Stock Exchange, Nasdaq Stockholm, and the NYSE. In September 2025, Michel Demaré, Chair, AstraZeneca, said, "Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future." European Update On Cancer Drug On Monday, the European Medicines Agency (EMA) validated the Type II Variation marketing authorization application for AstraZeneca's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer. Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The validation confirms the completion of the application and commences the scientific review process by the EMA's Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast09 phase 3 trial presented at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and subsequently published in The New England Journal of Medicine. In the trial, Enhertu in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab, and pertuzumab (THP). AZN Price Action: AstraZeneca shares were down 3.55% at $91.04 at the time of publication on Tuesday, according to Benzinga Pro data. Photo via Shutterstock